We are live on ! Find out more
CSCI

COSCIENS Biopharma Inc. Common Stock
CSCI

Delisted

CSCI was delisted on the 3rd of September, 2025.

Back to rankings

12 hedge funds and large institutions have $2.44M invested in COSCIENS Biopharma Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more capital invested

Capital invested by funds: $1.22M → $2.44M (+$1.22M)

33% more funds holding

Funds holding: 9 → 12 (+3)

Holders
12
Holders Change
+3
Holders Change %
+33.33%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$611K
2
Deutsche Bank
Deutsche Bank
Germany
+$505K
3
VKH
Virtu KCG Holdings
New York
+$66.4K
4
CS
Credit Suisse
Switzerland
+$53.2K
5
Morgan Stanley
Morgan Stanley
New York
+$26.6K

Top Sellers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$93K
2
HK
Horizon Kinetics
New York
-$26K
3
Creative Planning
Creative Planning
Kansas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$1.24M +$611K +46 +105%
Deutsche Bank
2
Deutsche Bank
Germany
$668K +$505K +38 +380%
BIT
3
BlackRock Institutional Trust
California
$145K – – –
VKH
4
Virtu KCG Holdings
New York
$99K +$66.4K +5 +250%
AG
5
Aperio Group
California
$85K – – –
CS
6
Credit Suisse
Switzerland
$50K +$53.2K +4 New
Morgan Stanley
7
Morgan Stanley
New York
$46K +$26.6K +2 +200%
Fifth Third Bancorp
8
Fifth Third Bancorp
Ohio
$23K – – –
Jane Street
9
Jane Street
New York
$19K +$13.3K +1 New
TRCT
10
Tower Research Capital (TRC)
New York
$18K +$13.3K +1 New
Two Sigma Investments
11
Two Sigma Investments
New York
$16K +$13.3K +1 New
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$14K -$93K -7 -88%
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$7K – – –
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$6K – – –
MFS
15
MSI Financial Services
Massachusetts
$4K – – –
Invesco
16
Invesco
Georgia
$2K – – –
AllianceBernstein
17
AllianceBernstein
Tennessee
$1K – – –
HK
18
Horizon Kinetics
New York
– -$26K -2 Closed
Creative Planning
19
Creative Planning
Kansas
– -$1K – –

CSCI Hedge Fund Activity: Q4 2013 in Review

12 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2013, worth a combined $2.44M — up 100% from $1.22M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CSCI positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $611K. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $93K.

  • 12 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2013, up from 9 in Q3 2013.
  • Funds reported $2.44M of COSCIENS Biopharma Inc. Common Stock stock for Q4 2013, up 100% quarter-over-quarter.
  • 4 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2013 and 1 closed out, a net change of +3 holders.
  • The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2013 was Renaissance Technologies, an estimated $611K added.
  • The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2013 was Cambridge Investment Research Advisors, an estimated $93K sold.

Based on aggregated 13F filings for Q4 2013.